V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
about
The past, present and future of immunotherapy against tumorRegeneration of stalled immune responses to transformed and infected cells using γδ T cellsγδ T cells for cancer immunotherapy: A systematic review of clinical trialsHarnessing the power of Vδ2 cells in cancer immunotherapyMembrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cellsAdoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.Plasticity of γδ T Cells: Impact on the Anti-Tumor ResponseSelective role of mevalonate pathway in regulating perforin but not FasL and TNFalpha release in human Natural Killer cellsClinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.Neuroblastoma killing properties of Vδ2 and Vδ2-negative γδT cells following expansion by artificial antigen-presenting cells.Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells.Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Immunoproteasomes and immunotherapy-a smoking gun for lung cancer?Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies.Human γδT-cell subsets and their involvement in tumor immunity.Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside.Combination strategies to enhance antitumor ADCC.The multifunctionality of human Vγ9Vδ2 γδ T cells: clonal plasticity or distinct subsets?Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy.Monitoring Circulating γδ T Cells in Cancer Patients to Optimize γδ T Cell-Based Immunotherapy.Regulatory and effector functions of gamma-delta (γδ) T cells and their therapeutic potential in adoptive cellular therapy for cancer.Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vδ 2 T lymphocytes in non-Hodgkin lymphomas.The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture.Human Vδ2 versus non-Vδ2 γδ T cells in antitumor immunity.Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood gammadelta T cells.Interleukin-18 activates Vγ9Vδ2+ T cells from HIV-positive individuals: recovering the response to phosphoantigen.Human γδ T lymphocytes for immunotherapeutic strategies against cancer.γδ T Cell-Mediated Antibody-Dependent Cellular Cytotoxicity with CD19 Antibodies Assessed by an Impedance-Based Label-Free Real-Time Cytotoxicity Assay.Dual Face of Vγ9Vδ2-T Cells in Tumor Immunology: Anti- versus Pro-Tumoral Activities.Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells.Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer.
P2860
Q26799896-DC20B74D-E477-4309-9339-F3A77339CDF7Q26823185-FF6DA1C0-D4B4-4C36-A245-C697DC64DB7CQ27021705-BF619273-5B22-42BC-887A-28AEFE699644Q27027547-58948AA1-F331-4B73-9D46-B6B6BD18D65EQ27309991-C806503A-CC32-4DA3-A4B5-7C5734BD1450Q33905819-740B03A0-2339-4450-B6F9-BF792BD62CC6Q34612619-3CA41BEC-9192-4C53-A194-9B7E171C20A0Q34652408-2359340C-B0B9-46C0-A0B6-A13E37304E64Q34717893-542CFFB1-134B-49E0-BCDC-3C54CB84B5DBQ35208161-65974A97-EAC5-4C71-A8BC-36A986D46E47Q35654544-4EA5FE07-053C-432C-8BB6-D3B2FA0FD993Q35883452-57EFBC82-7DE4-4489-B1D6-7F8D793E0370Q36597374-A818C7A3-5608-4AF3-B1D8-0AC841C1412CQ37121401-B339C23B-6A30-4D55-B26A-E6500B2E4FDCQ37224604-6ADEEF8E-8D3C-471C-9EBB-4CD57D3A32D0Q37714642-E813D044-34EC-4972-9C18-1F3CAA719AACQ37731978-EA9A7FE6-4A4E-49D0-9FF9-C616F77C6379Q37876363-13626580-1389-42ED-A346-060C20802EB3Q38014085-1BADB56C-1F26-40AC-BDF7-A1CB4203D3E3Q38016451-C4A4A9A6-89EA-4F26-AB89-C9F10C6D73DDQ38051222-CF8E8049-6632-427D-9321-198CB7811C6CQ38051730-D3D120E8-3CA7-45EF-A562-8D34D418379BQ38149725-77769DD7-49F4-4526-A553-CDDAAABCB6C2Q38151057-0B965E69-81D8-4699-B73F-0E16A0CB756FQ38174058-9E8A5521-7A4A-47B8-B7C0-A4E2CDD2E50AQ38179172-1DFF0672-C02F-47A6-918F-E891E346D7C4Q38271585-AE82FA6C-56A9-4CE2-81A4-7A5E4F3BC99EQ38310258-35F29C04-9B59-444F-9E7C-17C50FF44071Q38787725-42DDD00B-0AEF-4797-83A7-C017317006EAQ39158802-6C5C0CE3-8B1A-411F-BA95-CB8FCF004DA0Q39255203-CC54327F-23AF-4C9A-83C1-5F5C290BEC61Q39396311-7FF0F80A-DCDB-4FD3-86AB-F93FC11F1EF3Q39729244-4F3CDAD8-BA1C-444F-8BD6-1E9A1C2A171AQ40274003-92CD4BC6-B143-4E71-8A5B-43A5B024A777Q41812496-08FF46A6-AC19-480D-A4DD-881CBA3407ECQ41872171-A7328E4E-3DE9-4D7C-A706-F30924E3A144Q50144881-E3526880-6A38-4428-900C-318F5ADC9122Q52367095-543FC2F9-4117-4F29-AA6E-66D407A5E03CQ55240690-1189B1FC-E4EB-4562-82B5-098DAD65D051Q55311835-02A69980-B979-4EC9-A8B2-0EB5A120EF65
P2860
V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
V gamma 9 V delta 2 T cell cyt ...... gs--rituximab and trastuzumab.
@en
type
label
V gamma 9 V delta 2 T cell cyt ...... gs--rituximab and trastuzumab.
@en
prefLabel
V gamma 9 V delta 2 T cell cyt ...... gs--rituximab and trastuzumab.
@en
P2093
P2860
P356
P1476
V gamma 9 V delta 2 T cell cyt ...... gs--rituximab and trastuzumab.
@en
P2093
Andrew J Nicol
Fuminori Moriyasu
Hang-Fai So
Hirotake Tokuyama
Jacqueline Morley
Tomomi Hagi
P2860
P304
P356
10.1002/IJC.23365
P577
2008-06-01T00:00:00Z